Disruption of chromosome locus 3q26 is a rare but recurrent cytogenetic aberration that occurs in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Chromosome 3q26.2 abnormalities have been shown to activate EVI1 expression, in at least a subset of cases, and EVI1 plays an important role in pathogenesis by promoting myeloid proliferation and blocking differentiation. Among several types of 3q26 aberrations, the most common are inv(3) (q21q26.2)/t(3;3)(q21;q26.2) and t(3;21)(q26.2;q22), as seen in 22% and 7% of cases, respectively.
Disruption of chromosome locus 3q26 is a rare but recurrent cytogenetic aberration that occurs in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Chromosome 3q26.2 abnormalities have been shown to activate EVI1 expression, in at least a subset of cases, and EVI1 plays an important role in pathogenesis by promoting myeloid proliferation and blocking differentiation. Among several types of 3q26 aberrations, the most common are inv(3) (q21q26.2)/t(3;3)(q21;q26.2) and t(3;21)(q26.2;q22), as seen in 22% and 7% of cases, respectively.
AML associated with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) is recognized as a distinct entity in the 2008 World Health Organization (WHO) classification, included within the group of AML with recurrent genetic abnormalities. 1 These patients often present with anemia and the platelet count can be normal or increased. The bone marrow typically shows increased small hypolobated megakaryocytes and multilineage dysplasia. These patients are frequently refractory to conventional chemotherapy regimens and have a short overall survival. 2, 3 A small subset of MDS cases also are associated with inv(3)/t(3;3). Affected patients share many features with patients with AML associated with inv(3)/t(3;3) and in such patients, the disease has a propensity to progress rapidly to AML. We suggested previously that these patients with MDS are part of the spectrum of myeloid neoplasms associated with inv(3)/t(3;3).
By contrast, t(3;21)(q26.2;q22), reported in approximately 1% of MDS/AML cases, is less well understood. The pathologic features of these neoplasms are not well described and prognostic data are rarely available. [4] [5] [6] [7] [8] [9] [10] The cytogenetic Upon completion of this activity you will be able to:
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Questions appear on p 161. Exam is located at www.ascp.org/ajcpcme. abnormality involves 3q26.2, in common with inv(3)/t(3;3), therefore one might hypothesize that MDS/AML cases associated with these cytogenetic abnormalities are closely related, but few studies have addressed this issue in the literature. In this study, we report the clinicopathologic and cytogenetic features of a group of 17 patients with MDS or AML associated with t(3;21)(q26.2;q22). We further compare the clinicopathologic and prognostic features of this group with those of a group of 17 patients with MDS associated with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Lastly, we discuss the distinct features of t(3;21) cases in comparison with other therapy-related MDS/AML in general.
Materials and Methods
We searched the files of the Department of Hematopathology at The University of Texas MD Anderson Cancer Center for myeloid neoplasms with disruption of chromosome 3q26.2 detected by conventional cytogenetic analysis. The study period was October 1997 through June 2011. A total 17 cases of either MDS or AML associated with t(3;21)(q26.2;q22) were identified. The medical records of each case were reviewed. We compared this group with 17 MDS patients who had inv(3)(q21q26.2) or t(3;3)(q21;q26.2) examined from October 1997 to August 2007 and described previously. 11 This study was performed with the approval of the institutional review board of our institution.
Bone marrow aspirate smears and biopsy touch imprint slides were air-dried and stained with Wright-Giemsa. Bone marrow biopsy and aspirate clot specimens were fixed in formalin and 4-μm thick slides were stained with H&E. Slides were reviewed to confirm the diagnosis, and the neoplasms were classified according to the 2008 WHO scheme, incorporating the ancillary data.
Bone marrow aspirate specimens were prepared for conventional cytogenetic analysis using methods described previously. 12 Metaphases were banded by the standard GTG method. The karyotypes were reported according to the 2009 International System for Human Cytogenetic Nomenclatu re. 13 A subset of cases was assessed for RAS and/or FLT3/ITD or FLT3/D835 mutations using methods previously described. 14, 15 In 2 cases with available RNA, EVI1 expression was quantified by real-time polymerase chain reaction (PCR) using primers that cover exon I of EVI1 gene: forward primer, TTGCCAAG-TAACAGCTTTGCTG; reverse primer, CCAAAGGGTC-CGAATGTGACTT, and SYBR Green (Applied Biosystems, Foster City, CA)-based detection method.
Overall survival was calculated from date of diagnosis of either MDS or AML associated with t(3;21)(q26;q22) until date of death. Patient survival was analyzed using the KaplanMeier method and compared using the double-sided log-rank test (Mantel-Cox). Fisher exact test was used to analyze the differences between the 2 groups of patients. GraphPad Prism 5 (GraphPad Software Inc, La Jolla, CA) was used for statistical analysis. P < .05 was considered statistically significant.
Results

Clinical and Pathologic Features
We identified 17 patients with AML or MDS associated with t(3;21)(q26.2;q22). Sixteen patients had therapy-related MDS (t-MDS; n = 12) or AML (t-AML; n = 4) and 1 patient had de novo AML. The clinical and pathologic features of these patients are summarized in ❚Table 1❚.
Patients included 9 men and 8 women with a median age of 62 years (range, 13-81 years). All had anemia with a median hemoglobin level of 9. Bone marrow aspirate smears in all cases showed dysplasia involving the erythroid and/or myeloid lineages ❚Image 1B❚. Fifteen (88%) of 17 cases showed megakaryocytic hypoplasia. Small hypolobated megakaryocytes, as seen typically in cases of MDS or AML associated with inv(3)/t(3;3), were observed in 4 of 5 cases evaluable in this cohort ❚Image 1A❚, with only 1 case showing an increased number of megakaryocytes. The other 12 cases showed severe megakaryocytic hypoplasia precluding adequate morphologic assessment. The bone marrow blast count ranged from 1% to 15% in cases of t-MDS and 33% to 50% in t-AML. Bone marrow biopsy specimens were hypocellular in 7 cases, normocellular in 4 cases, and hypercellular in 1 case of t-MDS. Three t-AML cases were normocellular and 1 was hypocellular. The de novo AML case had evidence of granulocytic and megakaryocytic dysplasia in a hypercellular bone marrow.
The morphologic features of these cases are not specific. Although all MDS cases were classified as therapy-related, according to WHO classification criteria, the morphologic features were similar to refractory anemia, refractory cytopenia with multilineage dysplasia, or refractory anemia with excess blasts. Similarly, all AML cases except 1 were therapyrelated, and were classified as such, but showed minimal, granulocytic, or myelomonocytic differentiation. One case was associated with 66% erythroblasts and met criteria for acute erythroid leukemia. Using the older French-AmericanBritish classification, the AML cases would be classified as M0, M1, M2, M4, or M6. No cases in this study had M3, M5, or M7 morphologic characteristics.
For the group of patients with t-MDS or t-AML, the interval from primary tumor to development of MDS/AML associated with t(3;21) ranged from 9.2 to 151 months. The primary tumors included non-Hodgkin lymphoma (n = 5), acute leukemia (n = 3), breast carcinoma (n = 3), prostate carcinoma (n = 2), classic Hodgkin lymphoma (n = 1), plasma cell myeloma (n = 1), and 1 patient with concurrent prostatic and lung carcinoma (Table 1) . Each patient had relapses or metastases and were treated with multiple cycles of chemotherapy that spanned several years. The therapeutic B A ❚Image 1❚ Morphologic features of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with t(3;21)(q26.2;q22). A, Corresponding bone marrow biopsy specimen from a patient with t-MDS/AML showing disorganized hematopoiesis and hyperplasia of small hypolobated megakaryocytes (arrows) (H&E, ×200). B, Bone marrow aspirate smear showing dyserythropoiesis (arrow) and increased blasts (arrowhead) (Wright-Giemsa stain, ×1,000). agents used included idarubicin, doxorubicin, hydroxyurea, topotecan, thalidomide, fludarabine, decitabine, clofarabine, cytarabine, cyclophosphamide, and azacitidine. Three patients underwent allogeneic stem cell transplantation.
Clinical follow-up showed that all patients died after diagnosis of MDS or AML, with a median survival of 4.7 months (range, 0.2 to 28 months). In 7 of 12 patients with t-MDS, the disease progressed to AML.
Conventional Cytogenetic and Molecular Findings
Cytogenetic results for the study group revealed isolated t(3;21)(q26.2;q22) in 5 (29%) patients, including the single case of de novo AML. Twelve patients had additional cytogenetic aberrations. Monosomy 7/del(7q) was the most common abnormality, present in 9 (53%) patients. Trisomy 8 was detected in 3 (18%) patients, monosomy 5 in 1 (6%) patient, and a complex karyotype in 7 (41%) patients. All except one with complex cytogenetic findings also had -7/ del(7q).
The t(3;21) and -7/7q were detected simultaneously in 7 patients and sequentially in 2 patients. In the 2 sequentially detected cases, detection of -7 preceded that of t(3;21) by approximately 3 months, suggesting that t(3;21) evolved as a secondary event. In 1 of these 2 patients, emergence of t(3;21) was accompanied by a slight increase of bone marrow blasts, from 4% to 7%. Trisomy 8 was detected simultaneously with t(3;21) in 3 cases. RAS mutation (n = 6) and FLT3 (n = 3) mutations were not detected in all cases tested.
Two cases analyzed for EVI1 expression by quantitative reverse transcriptase PCR showed increased expression of EVI1 (1-1.5 fold) compared with normal controls.
Comparison of Patients With MDS Associated With t(3;21) vs MDS Associated With inv(3)/t(3;3)
We compa red the clinicopathologic and cytogenetic features of the study group with those of 17 patients with MDS associated with inv(3)/t(3;3) ❚Table 2❚. Overall, t(3;21) occurred almost exclusively in the therapy-related setting. In contrast, inv(3)/t(3;3) cases occurred either de novo or after therapy (n = 6) (P = .001). Small hypolobated megakaryocytes were observed in MDS/AML associated with t(3;21), as is common in inv(3)/t(3;3) cases of MDS/AML. However, cases of MDS/AML associated with t(3;21) often showed megakaryocytic hypoplasia, unlike inv(3)/t(3;3) cases that commonly show megakaryocytic hyperplasia. The frequency of -7/7q, -5/5q, or a complex karyotype was similar in both groups (P = .3, .2, and .7, respectively). 16 19 cases were MDS ❚Table 3❚, with the remaining cases being either AML or chronic myeloproliferative disorders in blast phase. t(3;21) is thought to result in translocation and fusion of part of the RUNX1 gene to MECOM (currently preferred designation for the MDS-EVI1 gene locus) located in the 3q26 region. The translocation is thought to aberrantly activate both RUNX1 and MECOM, and the fusion products play a pivotal role in pathogenesis of MDS and AML. The fusion products can block myeloid differentiation, promote proliferation and malignant transformation by exerting a dominant-negative effect over RUNX1-induced normal transcriptional activation, antagonize the growth-inhibitory effects of transforming growth factor, block JNK activity and therefore prevent stress-induced apoptosis, and enhance AP-1 activity. 17, 18 We and others have identified the presence of AML1/MDS1/EVI1 or other fusion transcripts in myeloid neoplasms associated with t(3;21). 5, 6, 8, 19 In this study, we report clinicopathologic, cytogenetic, and survival data for a large group of cases of MDS or AML associated with t(3;21)(q26.2;q22). We also compared these cases to the more common group of MDS/AML associated with inv(3q21q26.2) or t(3;3)(q21;q26.2). Similar to other MDS/AML cases with chromosome 3q26 locus abnormalities, myeloid neoplasms associated with t(3;21) usually display marked dysplasia. Blasts can exhibit minimal, myeloid, or monocytic differentiation and rarely these cases can mimic acute erythroid leukemia. Small hypolobated megakaryocytes are also noted. However, MDS/AML cases associated with t(3;21) do have some features that distinguish them from ❚Figure 1❚ Overall survival. A, Comparison of all patients with myelodysplastic syndrome/acute myeloid leukemia (MDS/ AML) associated with t(3;21) (n=17) vs inv(3)/t(3;3) (n=17). Patients with myeloid neoplasms associated with t(3;21) had significantly worse survival (P = .03). B, Comparison of therapy-related MDS/AML patients with t(3;21) (n=16) vs inv(3)/t(3;3) (n = 6). Patients with therapy-related myeloid neoplasms associated with t(3;21) had significantly worse survival (P = .047). C, Comparison of t(3;21)-associated MDS/AML with (n = 9) vs without (n = 8) additional -7/7q (P = .18). D, Comparison of patients with t(3;21)-associated MDS/AML with (n = 7) vs without (n = 10) a complex karyotype (P = .17). MDS/AML associated with inv(3)/t(3;3). In our experience, MDS/AML associated with t(3;21) occurs almost exclusively in the therapy-related setting, and commonly shows megakaryocytic hypoplasia, unlike the megakaryocytic hyperplasia usually present in cases of MDS/AML associated with inv(3)/t(3;3). No patients with t(3;21)-associated MDS/AML had thrombocytosis and only rarely did patients have a normal platelet count. Affected patients also had a very short overall survival (median, 4.7 months). Our results suggest that MDS/ AML associated with t(3;21) is a particularly poor prognostic subset that needs to be distinguished from other cases of MDS/AML associated with 3q26 abnormalities. This result differs from that reported by Lugthart and colleagues 20 who observed better survival for patients with AML with t(3;21) than those with inv(3)/t(3;3). Lymphoid neoplasms or breast cancers are usually the primary tumors in patients with t-MDS/AML in general, accounting for about 35% and 24% of cases, respectively. 21 In this study of 16 patients with t-MDS/AML carrying t(3;21), 6 (38%) were previously treated for lymphoma and 3 (19%) for breast cancer. When we compared these cases with the 6 cases of t-MDS/AML carrying inv(3)/t(3;3) in this study, we found that the latter group occurred more commonly in patients treated for lymphomas (5 [83%] of 6). t-MDS/AML associated with t(3;21), in contrast, occurred in patients with a wider spectrum of tumors including lymphomas, leukemias, plasma cell myeloma, and solid tumors. Obviously the small sample size precludes definite conclusions. However, one can speculate that differences in chemotherapeutic regimens used to treat patients with lymphoma compared with those with other tumors may predispose patients to either inv(3)/t(3;3) or t(3;21).
❚Table 2❚ Comparison of Clinical Features of MDS/AML With t(3;21) vs MDS With inv(3)/t(3;3)
Features t(3;21) (n = 17) inv(3) or t(3;3) (n = 17)
Two categories of t-MDS/AML are well recognized. Those associated with unbalanced loss of genetic material, including chromosomes 5 and/or 7 are usually associated with exposure to alkylating agents, whereas balanced chromosomal translocations are typically associated with exposure to inhibitors of DNA topoisomerase II. 22 The former has a latency period of 5 to 10 years compared with 1 to 5 years in the latter group after treatment of primary tumors. However, most patients usually are treated with both types of agents and a distinction cannot be made easily. In fact, most patients in the study group received both alkylating agents and DNA topoisomerase II inhibitors for their primary tumors. In addition to the balanced t(3;21), deletion of 7/7q, +8 and/ or a complex karyotype occurred in 53%, 18%, and 41% of cases, respectively. The latency interval from the time of primary malignancy to the onset of t-MDS/AML in this study group also followed the general patterns described for the 2 categories of t-MDS/AML spanning from 9.2 months to 151 months. Stein et al 23 suggested that development of monosomy 7 may result from EVI1 activation-induced genomic instability. However, monosomy 7 occurred before the t(3;21) in 2 cases of our study arguing against this hypothesis. It is not clear from our results what general type of therapy is associated with genesis of t(3;21).
Therapy-related myeloid neoplasms, in general, have a poor prognosis, with 5-year survival rates of less than 10%. It is believed that patients with balanced translocations usually have a better prognosis, whereas patients with chromosome 7 abnormalities or a complex karyotype have a particularly poor prognosis, with a median survival of less than 1 year. 22 Similarly, in this study, 65% of our patients died within 1 year and all patients died within 2 years and 4 months. However, a finding unique to our patients was that regardless of whether the chromosomal aberration identified was an isolated t(3;21) or a complex karyotype, all our patients had a poor prognosis, indicating t(3;21) alone was a significant adverse factor. In summary, we have described 17 patients with either MDS or AML associated with t(3;21)(q26.2;q22). These tumors share some similarity with cases of MDS/AML associated with inv(3q21q26.2) or t(3;3)(q21;q26.2). In particular, cases of MDS/AML associated with t(3;21) usually show marked multilineage dysplasia and frequent association with -7 and a complex karyotype. However, unlike cases associated with inv(3)/t(3;3), cases of MDS/AML associated with t(3;21) occur almost exclusively after chemotherapy and are associated with a very poor prognosis. We therefore conclude that MDS/ AML associated with t(3;21)(q26.2;q22) is a distinct entity.
